1. Home
  2. ELWS vs HOTH Comparison

ELWS vs HOTH Comparison

Compare ELWS & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Earlyworks Co. Ltd.

ELWS

Earlyworks Co. Ltd.

HOLD

Current Price

$5.46

Market Cap

16.4M

Sector

N/A

ML Signal

HOLD

Logo Hoth Therapeutics Inc.

HOTH

Hoth Therapeutics Inc.

HOLD

Current Price

$1.13

Market Cap

18.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ELWS
HOTH
Founded
2018
2017
Country
Japan
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.4M
18.0M
IPO Year
2023
2019

Fundamental Metrics

Financial Performance
Metric
ELWS
HOTH
Price
$5.46
$1.13
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$4.50
AVG Volume (30 Days)
24.9K
219.2K
Earning Date
12-31-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,083,071.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
145.52
N/A
52 Week Low
$1.64
$0.66
52 Week High
$10.50
$3.80

Technical Indicators

Market Signals
Indicator
ELWS
HOTH
Relative Strength Index (RSI) 55.46 39.99
Support Level $5.38 $1.16
Resistance Level $6.11 $1.25
Average True Range (ATR) 0.30 0.06
MACD -0.05 0.01
Stochastic Oscillator 48.38 3.33

Price Performance

Historical Comparison
ELWS
HOTH

About ELWS Earlyworks Co. Ltd.

Earlyworks Co Ltd is a blockchain-based technology company. It builds products, delivers services, and develops solutions based on a proprietary grid ledger system to leverage blockchain technology in various business settings, including advertisement tracking, online visitor management, and sales of non-fungible tokens. The company's customers represent a diverse range of industries, such as information technology, shipping, real estate, entertainment, cosmetics, and chemical products.

About HOTH Hoth Therapeutics Inc.

Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).

Share on Social Networks: